Greenwich LifeSciences (GLSI)

• Market cap: $291M
• 1 day: 1.18%
• 5 days: -11.13%
• 1 month: -10.45%
• 3 months: -23.2%
• 6 months: -26.2%
• Year to date: 1.69%
• 1 year: 76.47%
• 5 years: -56.32%
• 10 years: 296%
• Sector: Healthcare
• Industry: Biotechnology

About: Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.

Employees: 13